Attention deficit hyperactivity disorder (ADHD) affects between 5% and 7% of the child population and 2.5% of adults worldwide, according to the most recent epidemiological data. In recent years, neurofeedback has been proposed as a complementary intervention for managing the core symptoms of the disorder —inattention, hyperactivity and impulsivity— and has generated an intense scientific debate about its true therapeutic scope.
In this clinical guide we review the evidence available up to 2025, the most studied protocols, the methodological limitations of the research and the possible role of neurofeedback within a multimodal approach to ADHD. Our aim is to offer a balanced view, based on the best available evidence, to help healthcare professionals and families make informed decisions.
Neurofeedback —also known as electroencephalographic biofeedback or EEG biofeedback— is a non-invasive neuromodulation technique based on the principles of operant conditioning. During a neurofeedback session, the patient's cerebral electrical activity is recorded by electroencephalography (EEG) and real-time information about certain parameters of their brain activity is provided, usually through a visual or auditory interface (for example, a video game or animation).
The underlying principle is that, by receiving this immediate feedback, the patient can learn to voluntarily modulate certain patterns of cortical activity. The training targets EEG frequencies or components considered to be altered in the disorder being addressed. In the case of ADHD, the most studied protocols focus on two main approaches: theta/beta ratio training and slow cortical potential (SCP) training.
It is important to distinguish neurofeedback from other forms of brain stimulation (such as transcranial direct current stimulation or transcranial magnetic stimulation), since neurofeedback does not apply any electrical signal to the brain: it merely records activity and provides information to the patient so that they actively modify their brain patterns.
The theoretical basis of neurofeedback in ADHD is supported by electroencephalographic alterations described in a relevant subgroup of patients. Since the 1990s, multiple studies have documented an increase in theta activity (4–8 Hz) and a reduction in beta activity (13–30 Hz) in frontocentral regions in children and adolescents with ADHD, resulting in an elevation of the so-called theta/beta ratio (Monastra et al., 1999; Arns et al., 2013).
However, subsequent research has considerably nuanced this observation. The meta-analysis by Arns et al. (2013) confirmed the existence of an elevated theta/beta ratio as a group finding, but also showed significant heterogeneity: not all patients with ADHD present this pattern. Indeed, the FDA withdrew in 2023 the approval of the theta/beta ratio as an auxiliary diagnostic biomarker for ADHD, recognising that its individual clinical utility is limited.
This fact is relevant because it suggests that, if neurofeedback targeting the theta/beta ratio works, it is likely to do so preferentially in those patients who actually present this alteration, which supports the need for an individualised neurophysiological assessment before beginning training.
This is the classic and most studied protocol. The goal is for the patient to learn to reduce theta activity (associated with low alertness or drowsiness) and increase beta activity (associated with focused attention states). It is typically performed with an electrode at Cz or Fz (frontocentral midline) and between 30 and 40 sessions of 30–45 minutes are used, at a frequency of 2–3 sessions per week.
Early studies, many of them open-label or with non-blinded assessors, showed significant improvements in symptoms of inattention and hyperactivity, with moderate to large effect sizes. However, as we will see later, these results are substantially attenuated when blinded assessors are used.
This protocol focuses on teaching the patient to regulate slow cortical potentials, which are low-frequency voltage changes (<1 Hz) that reflect the level of cortical excitability. The patient learns to generate both negativisations (increased cortical excitability, associated with preparation for action and attention) and positivations (reduced excitability, associated with inhibition and rest). The therapeutic principle is that patients with ADHD have difficulties in the self-regulation of these cortical thresholds.
Clinical trials by Strehl et al. (2006) and Gevensleben et al. (2009) provided promising data for this protocol, which has also been included in ISNR guidelines as an intervention with evidence of «probable efficacy» to «efficacious».
Other modalities have been investigated, such as sensorimotor rhythm (SMR, 12–15 Hz) training, protocols based on evoked potentials, and approaches using real-time functional MRI neurofeedback (rt-fMRI neurofeedback). However, the evidence for these protocols in ADHD is still insufficient to draw clinical conclusions, and their application is currently limited to the research field.
The evaluation of the evidence on neurofeedback in ADHD has been the subject of multiple meta-analyses and systematic reviews. Results vary markedly depending on the methodology used, and it is essential to distinguish between probably blinded and probably non-blinded measures.
This influential meta-analysis, published in the Journal of the American Academy of Child & Adolescent Psychiatry, analysed 13 randomised controlled trials. Results showed a significant effect of neurofeedback on inattention symptoms when parent ratings (non-blinded assessors) were used, with a moderate effect size (SMD = 0.38). However, when only ratings from probably blinded assessors (teachers unaware of the assigned group) were considered, the effect was no longer statistically significant (SMD = 0.15; p > 0.05).
This finding highlighted the critical importance of blinding in neurofeedback trials and suggests that part of the observed improvement may be mediated by expectations, therapeutic attention or placebo effect.
The Bussalb et al. meta-analysis expanded the analysis with more recent studies and confirmed the general trend: significant effects in non-blinded ratings and reduced or non-significant effects in blinded measures. The authors concluded that the evidence is «promising but insufficient to recommend neurofeedback as a first-line treatment».
The International Society for Neurofeedback and Research (ISNR), in its review of evidence-based guidelines, classified neurofeedback protocols for ADHD with an evidence level of «efficacious» (Level 5, the maximum) for standard protocols (theta/beta and SCP). However, this classification has been debated by other research groups who consider that the ISNR criteria are less demanding than the usual standards of evidence-based medicine, particularly regarding blinding.
It is relevant to note that the ISNR itself acknowledges that more trials with sham-controlled designs (with placebo neurofeedback) are needed to resolve discrepancies between blinded and non-blinded studies.
The ICAN (International Collaborative ADHD Neurofeedback) randomised clinical trial, published in the Journal of the American Academy of Child & Adolescent Psychiatry, compared TBR neurofeedback with an active control group (cognitive training) in 142 children with ADHD. Results did not show significant superiority of neurofeedback over the active control on the primary measures of ADHD symptoms rated by blinded assessors, although both groups improved relative to baseline.
One of the most frequently cited arguments in favour of neurofeedback is the persistence of long-term benefits. Several 6–12 month follow-up studies have suggested that improvements obtained with neurofeedback tend to be maintained, unlike stimulant medication, whose effects cease when treatment is discontinued (Gevensleben et al., 2010; Strehl et al., 2017). However, these follow-up studies also have limitations: participant dropout, absence of blinded measures and the possibility that other concurrent interventions explain the results.
| Protocol | ISNR classification | Evidence in blinded measures | Effect size (blinded measures) |
|---|---|---|---|
| Theta/beta (TBR) | Level 5 — Efficacious | Inconsistent | Small to non-significant |
| SCP | Level 4-5 — Efficacious / Probably efficacious | Limited, some positive results | Small |
| SMR | Level 3 — Probably efficacious | Insufficient | Not determined |
Research on neurofeedback in ADHD has several limitations that are essential to understand in order to correctly interpret the results:
Taking into account the current state of evidence, neurofeedback may be considered as a complementary option in the following clinical scenarios:
In any case, the decision to incorporate neurofeedback must be made in the context of an individualised clinical assessment, with realistic expectations and without abandoning interventions with a higher level of evidence (pharmacotherapy, cognitive-behavioural therapy, school adaptations).
«Neurofeedback is not a single or universal solution. The evidence suggests that it may contribute to the improvement of certain symptoms in some patients, but always as part of an individualised and multidisciplinary programme.»
At GNeuro we integrate neurotechnology within a rigorous, evidence-oriented clinical model. Our philosophy is based on several fundamental principles:
As a specialist centre in robotic neurorehabilitation in Ourense, we maintain a commitment to constant scientific updating and to the application of technologies that have adequate support in the clinical literature.
Can neurofeedback replace medication for ADHD?
No. Current evidence does not support the use of neurofeedback as a replacement for stimulant medication, which remains the treatment with the highest level of evidence for ADHD. Neurofeedback may be considered as a complement within a multimodal therapeutic plan, always under professional supervision and without withdrawing medication prescribed by the responsible physician.
How many neurofeedback sessions are needed to observe changes in ADHD?
The most rigorous research protocols use between 25 and 40 sessions, distributed over 2–3 sessions per week. However, the response varies between individuals and not all patients respond in the same way. It is important to maintain realistic expectations: possible benefits are usually assessed after completing the full protocol and immediate results should not be expected.
Which neurofeedback protocol has the best evidence for ADHD?
The protocols with the greatest support in the literature are slow cortical potential (SCP) training and the theta/beta ratio protocol. According to ISNR guidelines, both protocols have an evidence level between «probable efficacy» and «efficacious», although trials with blinded measures show smaller effect sizes than studies with non-blinded assessors.
Is neurofeedback safe for children with ADHD?
EEG-based neurofeedback is a non-invasive technique that generally has a favourable safety profile. Adverse effects described in the literature are infrequent and usually mild (transient fatigue, mild headache after the session). However, it should always be applied by qualified professionals within an appropriate clinical framework. It is not recommended as an isolated intervention without prior medical assessment.
At GNeuro we assess each case individually to determine which interventions have the best evidence for your specific clinical situation.
Request an assessment